CN104169284B - 双环吡嗪酮衍生物 - Google Patents

双环吡嗪酮衍生物 Download PDF

Info

Publication number
CN104169284B
CN104169284B CN201380017205.4A CN201380017205A CN104169284B CN 104169284 B CN104169284 B CN 104169284B CN 201380017205 A CN201380017205 A CN 201380017205A CN 104169284 B CN104169284 B CN 104169284B
Authority
CN
China
Prior art keywords
pyrazine
ketone
phenyl
pyrrolo
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380017205.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104169284A (zh
Inventor
D.多施
H-P.布赫施塔勒
G.莫伊内特
A.韦格纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104169284(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN104169284A publication Critical patent/CN104169284A/zh
Application granted granted Critical
Publication of CN104169284B publication Critical patent/CN104169284B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380017205.4A 2012-03-28 2013-03-19 双环吡嗪酮衍生物 Active CN104169284B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12002215.7 2012-03-28
EP12002215 2012-03-28
PCT/EP2013/000827 WO2013143663A1 (en) 2012-03-28 2013-03-19 Bicyclic pyrazinone derivatives

Publications (2)

Publication Number Publication Date
CN104169284A CN104169284A (zh) 2014-11-26
CN104169284B true CN104169284B (zh) 2017-03-29

Family

ID=48013911

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380017205.4A Active CN104169284B (zh) 2012-03-28 2013-03-19 双环吡嗪酮衍生物

Country Status (31)

Country Link
US (1) US9120805B2 (enExample)
EP (1) EP2831077B1 (enExample)
JP (1) JP6096879B2 (enExample)
KR (1) KR102070567B1 (enExample)
CN (1) CN104169284B (enExample)
AR (1) AR090496A1 (enExample)
AU (1) AU2013242492B2 (enExample)
CA (1) CA2868620C (enExample)
CL (1) CL2014002557A1 (enExample)
CO (1) CO7111292A2 (enExample)
DK (1) DK2831077T3 (enExample)
EA (1) EA027416B1 (enExample)
EC (1) ECSP14024526A (enExample)
ES (1) ES2585044T3 (enExample)
HR (1) HRP20160908T1 (enExample)
HU (1) HUE030067T2 (enExample)
IL (1) IL234713A (enExample)
MX (1) MX351149B (enExample)
MY (1) MY172308A (enExample)
NZ (1) NZ630489A (enExample)
PE (1) PE20142186A1 (enExample)
PH (1) PH12014501829A1 (enExample)
PL (1) PL2831077T3 (enExample)
PT (1) PT2831077T (enExample)
RS (1) RS54997B1 (enExample)
SG (1) SG11201405750YA (enExample)
SI (1) SI2831077T1 (enExample)
TW (1) TWI576346B (enExample)
UA (1) UA112795C2 (enExample)
WO (1) WO2013143663A1 (enExample)
ZA (1) ZA201407828B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2822656B1 (en) 2012-03-07 2016-10-19 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
KR102070567B1 (ko) 2012-03-28 2020-01-29 메르크 파텐트 게엠베하 바이시클릭 피라지논 유도체
WO2013189905A1 (en) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Pyrrolopyrazone inhibitors of tankyrase
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
LT3087076T (lt) 2013-12-23 2017-12-27 Merck Patent Gmbh Imidazopirazinono dariniai
WO2016006974A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
KR101739003B1 (ko) 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
HUE054371T2 (hu) 2014-12-05 2021-09-28 Array Biopharma Inc 4,6-szubsztituált pirazolo[l,5-A]pirazinok mint janus kináz inhibitorok
HK1255269A1 (zh) 2015-08-17 2019-08-09 Lupin Limited 作为parp抑制剂的杂芳基衍生物
AU2017222417B2 (en) 2016-02-24 2020-07-09 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as JAK-inhibitors
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
EP3668858A1 (en) 2017-08-14 2020-06-24 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl and related derivatives
EP3793559A1 (en) * 2018-05-17 2021-03-24 Bayer Aktiengesellschaft Substituted dihydropyrazolo pyrazine carboxamide derivatives
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds
GB2632441A (en) * 2023-08-08 2025-02-12 Duke Street Bio Ltd Deuterated PARP1 inhibitor compounds
WO2025084446A1 (ko) * 2023-10-16 2025-04-24 에스티팜 주식회사 트리아졸로피리미디논 유도체의 결정형

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090209523A1 (en) * 2006-05-31 2009-08-20 Philip Jones Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp)
US20110053929A1 (en) * 2007-07-11 2011-03-03 Bayer Schering Pharma Aktiengesellschaft Imidazo-, pyrazolopyrazines and imidazotriazines and their use
CN102229611A (zh) * 2011-04-26 2011-11-02 山东大学 2,6-二芳基吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PL194689B1 (pl) 1996-02-13 2007-06-29 Astrazeneca Uk Ltd Pochodne chinazoliny, ich kompozycje farmaceutyczne oraz ich zastosowania
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
WO2008082887A2 (en) * 2006-12-28 2008-07-10 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
CA2678248C (en) 2007-03-08 2016-06-28 Janssen Pharmaceutica Nv Quinolinone derivatives as parp and tank inhibitors
WO2009130232A1 (en) 2008-04-24 2009-10-29 Glaxo Group Limited Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
WO2009130231A1 (en) 2008-04-24 2009-10-29 Glaxo Group Limited Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
WO2010043676A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
CA2787714C (en) 2010-01-22 2019-04-09 Joaquin Pastor Fernandez Inhibitors of pi3 kinase
US8450320B2 (en) * 2010-04-16 2013-05-28 Abbvie Inc. Pyrrolopyrazinone inhibitors of kinases
KR102070567B1 (ko) 2012-03-28 2020-01-29 메르크 파텐트 게엠베하 바이시클릭 피라지논 유도체
WO2013189905A1 (en) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag Pyrrolopyrazone inhibitors of tankyrase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090209523A1 (en) * 2006-05-31 2009-08-20 Philip Jones Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp)
US20110053929A1 (en) * 2007-07-11 2011-03-03 Bayer Schering Pharma Aktiengesellschaft Imidazo-, pyrazolopyrazines and imidazotriazines and their use
CN102229611A (zh) * 2011-04-26 2011-11-02 山东大学 2,6-二芳基吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
2-甲基-3-取代苯基吡咯并吡嗪酮类化合物的合成及抗癌活性研究;马鹤，等;《中国药物化学杂志》;20100630;第20卷(第3期);第171-175页，Figure 1，Table 2，合成实验部分 *

Also Published As

Publication number Publication date
PH12014501829B1 (en) 2014-11-10
US20150057264A1 (en) 2015-02-26
TW201343650A (zh) 2013-11-01
EA027416B1 (ru) 2017-07-31
KR20140140099A (ko) 2014-12-08
CA2868620C (en) 2020-02-25
CN104169284A (zh) 2014-11-26
EP2831077B1 (en) 2016-04-27
CO7111292A2 (es) 2014-11-10
MY172308A (en) 2019-11-21
SI2831077T1 (sl) 2016-09-30
ES2585044T3 (es) 2016-10-03
DK2831077T3 (en) 2016-08-15
MX351149B (es) 2017-10-04
CL2014002557A1 (es) 2014-12-19
NZ630489A (en) 2016-04-29
PT2831077T (pt) 2016-08-12
JP6096879B2 (ja) 2017-03-15
AU2013242492A1 (en) 2014-11-13
IL234713A (en) 2016-09-29
UA112795C2 (uk) 2016-10-25
WO2013143663A1 (en) 2013-10-03
JP2015511609A (ja) 2015-04-20
HRP20160908T1 (hr) 2016-09-23
PE20142186A1 (es) 2014-12-29
PL2831077T3 (pl) 2016-10-31
RS54997B1 (sr) 2016-11-30
ZA201407828B (en) 2015-12-23
TWI576346B (zh) 2017-04-01
AU2013242492B2 (en) 2016-12-15
US9120805B2 (en) 2015-09-01
AR090496A1 (es) 2014-11-19
MX2014011420A (es) 2014-11-25
HUE030067T2 (en) 2017-04-28
ECSP14024526A (es) 2015-09-30
KR102070567B1 (ko) 2020-01-29
SG11201405750YA (en) 2014-10-30
HK1203961A1 (en) 2015-11-06
CA2868620A1 (en) 2013-10-03
PH12014501829A1 (en) 2014-11-10
EP2831077A1 (en) 2015-02-04
EA201401062A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
CN104169284B (zh) 双环吡嗪酮衍生物
CN104507912B (zh) (氮杂-)异喹啉酮衍生物
CN104271580B (zh) 吡咯并三嗪酮衍生物
CN104662006B (zh) 作为parp抑制剂的喹唑酮衍生物
CN104093714B (zh) 作为tank和parp抑制剂的四氢-喹唑啉酮衍生物
HK1203961B (en) Bicyclic pyrazinone derivatives
HK1205740B (en) Pyrrolotriazinone derivatives
HK1209106B (en) (aza-)isoquinolinone derivatives
HK1202551B (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203961

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1203961

Country of ref document: HK